NCT02705638 - Treatment of IgG4-Related Disease With Revlimid and Rituximab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions

Immunoglobulin G Subclass 4 Related DiseaseIgG4-related DiseaseAutoimmune PancreatitisIgG4-related Sclerosing CholangitisRetroperitoneal Fibrosis

Interventions

DRUG

Rituximab

All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.

DRUG

Lenalidomide

All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.

Trial Locations (1)

Mayo Clinic in Rochester, Rochester